

# Use Of Viral Il-6 To Modulate Monocyte Differentiation To Boost Anti-Tumor Immunity

Tech ID: 33317 / UC Case 2022-582-0

## ABSTRACT

Researchers at the University of California, Davis have developed a virally derived homolog to increase the inflammatory response desirable in cancer immunotherapy.

## FULL DESCRIPTION

Researchers at the University of California Davis have developed the use of a virally derived homolog of interleukin-6 (vIL-6) to increase the inflammatory response desirable in cancer immunotherapy. The technology promotes dendritic cell differentiation and M1 macrophage differentiation from monocytes, unlike human IL-6, and doesn't trigger anti-inflammatory negative feedback mechanisms. The technology includes the RNA- and viral vector-based delivery of vIL-6-encoding nucleic acids.

Unlike IL-6, vIL-6 does not trigger negative feedback regulation, thus providing a unique benefit when it's used therapeutically as it does not limit its own efficacy by self-downregulation. This new technology aims to enhance cancer therapy by combining the administration of vIL-6 with an anti-cancer therapeutic agent, especially an anti-cancer immunotherapeutic agent.

## APPLICATIONS

- ▶ Development of new medication and treatments for cancer
- ▶ Potential use in research and development in the medical and pharmaceutical industry
- ▶ Useful in the field of cancer therapeutics, specifically in immunotherapy
- ▶ Potential application in the manufacturing of cell culture mediums
- ▶ May be incorporated into various delivery systems such as viral vector-based delivery, liposomal formulations, transdermal patches, etc for treating cancer

## FEATURES/BENEFITS

- ▶ Increases the inflammatory response desirable in cancer therapies
- ▶ Promotes dendritic cell differentiation and M1 macrophage differentiation
- ▶ Utilizes RNA- and viral vector-based delivery for effective implementation
- ▶ Does not self-downregulate which is an issue with existing therapies that are limited by negative feedback mechanisms
- ▶ Can be applied in various formats such as protein form or nucleic acid form
- ▶ Potential supplement for cell culture to enhance the recovery and efficacy of dendritic cells

## PATENT STATUS

Country	Type	Number	Dated	Case
---------	------	--------	-------	------

## CONTACT

Prabakaran  
 Soundararajan  
[psoundararajan@ucdavis.edu](mailto:psoundararajan@ucdavis.edu)  
 tel: .



## INVENTORS

- ▶ Izumiya, Yoshihiro
- ▶ Shimoda, Michiko

## OTHER INFORMATION

### CATEGORIZED AS

- ▶ **Medical**
  - ▶ Disease: Cancer
  - ▶ Gene Therapy
  - ▶ New Chemical Entities, Drug Leads
  - ▶ Therapeutics
- ▶ **Research Tools**
  - ▶ Nucleic Acids/DNA/RNA
  - ▶ Protein Synthesis

### RELATED CASES

2022-582-0

Additional Patent Pending

### **ADDITIONAL TECHNOLOGIES BY THESE INVENTORS**

- ▶ [Transcription Active Complex Targeting Cancer Drug From Viral Protein Sequence](#)
- ▶ [CHD4 Targeting Peptide Isolated From Viral Protein For Cancer Therapeutics](#)
- ▶ [Cellular Protein CDH4 Inhibiting Peptide](#)

**University of California, Davis**

**Technology Transfer Office**

1 Shields Avenue, Mrak Hall 4th Floor,  
Davis, CA 95616

Tel:

530.754.8649

[techtransfer@ucdavis.edu](mailto:techtransfer@ucdavis.edu)

<https://research.ucdavis.edu/technology-transfer/>

Fax:

530.754.7620

© 2023, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)